Head and Neck Cancer Treatment Market by Route Of Administration, Therapy and Geography - Forecast and Analysis 2023-2027

Head and Neck Cancer Treatment Market Report 2023-2027:

The head and neck cancer treatment market size is estimated to grow by USD 5,077.38 million at a CAGR of 11.27% between 2022 and 2027. 

The growing geriatric population is a significant factor shaping the growth of the head and neck cancer treatment market.  The human body tends to lose its immunity and self-healing power with aging, which makes it prone to different chronic indications such as cancer. The rising geriatric population is significant across the world, and the prevalence of cancer is rising, consequently contributing to strong demand for diagnostic, assistance, maintenance, and treatment-related equipment. 

However, according to The World Bank Group, the geriatric population increased from 8% to 9% of the total global population during the years 2015-2020. Moreover, the incidence of head and neck cancers is increasing in the geriatric population. The incidence of newly diagnosed head and neck cases among the elderly population is expected to rise by over 55% by 2030 globally. Combined modality treatment that incorporates chemotherapy and radiation therapy is frequently necessary to maximize the control of tumors in most patients with SCCHN. Nevertheless, the treatment of head and neck cancer involving multimodality therapy treatment can be quite difficult. The expanded rates of oral HPV infections and HPV-driven cancers, therefore, lead to an expanded incidence of oral SCC among elderly patients. Over the age of 55 years, in the UK, about 2 out of 3 cases of mouth cancer are diagnosed in adults. Thus, the rising geriatric population increases the demand for head and neck cancer treatment procedures for the early detection of the disease globally. Such a factor is likely to positively driving market growth.

Technavio has segmented the market into the route of administration, therapy and geography.

• The route of administration segment includes injectable and oral.
• The therapy segment includes immunotherapy, targeted therapy, and chemotherapy.
• The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the size of the Head and Neck Cancer Treatment Market During the Forecast Period?

To learn more about this report, Request a Free Sample

Head and Neck Cancer Treatment Market Segmentation by Route Of Administration, Therapy and Geography Analysis

Rout of administration analysis 

Injectable drugs

The market share growth by the injectable segment will be significant during the forecast period. Injectable drugs are administered directly into the bloodstream, making them a suitable and convincing treatment option for patients. The injectable drugs segment includes different types of drugs, such as chemotherapy agents, targeted therapies, immunotherapy, and supportive care medications. 

Get a glance at the market contribution of various segments View a PDF Sample

The injectable segment was valued at USD 3,913.34 million in 2017. Cisplatin is one of the injectable drugs used in head and neck cancer treatment a chemotherapy agent that is commonly used in combination with other drugs to treat various types of cancers, including head and neck cancer. It works by damaging the deoxyribonucleic acid (DNA) of cancer cells, inhibiting their growth and spread. Cisplatin is administered intravenously, allowing the targeted and efficient delivery of the drug to cancer cells. Also, immunotherapy drugs in head and neck cancer treatment, such as pembrolizumab and nivolumab, are also generally administered through injection. These drugs work by stimulating the body's immune system to recognize and attack cancer cells. Injectable immunotherapy options are advantageous as they provide systemic effects and can reach various tumor sites throughout the body. The convenience and efficiency of injectable drugs permit the precise and controlled delivery of the medication, assuring maximum efficacy. In addition, the development of novel injectable formulations with improved pharmacokinetics and fewer side effects has expanded the demand for injectable drugs further in head and neck cancer treatment. Therefore, such factors are anticipated to expand the demand for injectable drugs and therapies for treating head and neck cancer treatment, which will drive the growth of the injectable segment of the global head and neck cancer treatment market during the forecast period.

Therapy Analysis 

Immunotherapy

Immunotherapy refers to the use of substances, such as monoclonal antibodies, vaccines, and immune checkpoint inhibitors, to enhance the body's immune system and specifically target cancer cells. This approach has shown promising results in treating head and neck cancer patients, leading to its increasing adoption in clinical practice. For instance, immunotherapy in the head and neck cancer treatment market is the use of immune checkpoint inhibitors. These inhibitors, such as pembrolizumab and nivolumab, block the interaction between cancer cells and immune cells, thereby permitting the immune system to recognize and attack the cancer cells. Moreover, clinical trials have demonstrated that these inhibitors can enhance survival rates and quality of life, especially for head and neck cancer patients, particularly those in advanced stages of the disease. Another illustration of immunotherapy in the head and neck cancer treatment market is the development of therapeutic vaccines. These vaccines are designed to stimulate the immune system to recognize and destroy cancer cells. The rise in the use of immunotherapy in the head and neck cancer treatment market can be attributed to its efficacy and favourable safety profile. Unlike traditional treatments such as chemotherapy and radiotherapy, which can have side effects, immunotherapy tends to have fewer negative effects. This makes it a more attractive option for patients, especially those who may not tolerate or respond well to conventional therapies. Therefore, such factors are anticipated o expand the demand for immunotherapy for treating head and neck cancer, which will drive the growth of the immunotherapy segment of the head and neck cancer treatment market during the forecast period.

Targeted therapy

Targeted therapy refers to a treatment procedure that particularly targets cancer cells or their surrounding environment while sparing healthy cells. This precision targeting assures that anti-cancer drugs are supplied to the intended site and cells, thereby hindering the growth of cancer cells effectively without causing unnecessary harm to surrounding healthy tissues. One instance of targeted therapy is the use of monoclonal antibodies. Monoclonal antibodies are laboratory-produced proteins that can bind to specific molecules in cancer cells. Moreover, by particularly targeting these molecules, monoclonal antibodies can interfere with the growth and spread of cancer cells. The use of targeted therapy in head and neck cancer treatment has revolutionized the field, delivering new hope for patients. By particularly targeting cancer cells and their signalling pathways, targeted therapies can often achieve better outcomes with fewer side effects than conventional chemotherapy or radiation therapy, which can damage both cancerous and healthy cells indiscriminately. Therefore, such factors are expected to augment the demand for targeted therapy for treating head and neck cancer treatment, which will fuel the growth of the targeted therapy segment in the head and neck cancer treatment market during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to account for 41% of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. This region holds a significant position in the head and neck cancer treatment market. North America, in recent years, has witnessed substantial growth, due to various factors, such as advancements in medical technology, increasing healthcare infrastructure, and a high prevalence of head and neck cancer cases. The major factors contributing to the growth of the head and neck cancer treatment market in North America are the presence of well-established healthcare facilities and a robust pharmaceutical R&D industry. For instance, the Center for Head and Neck Cancers, which is part of the Massachusetts General Hospital, is among the largest centers in New England and is dedicated to patients with head and neck cancers, including complex and rare forms of the disease. Physicians at the Center for Head and Neck Cancers have deep expertise in treating these rare types of cancer. The radiation and medical oncology specialists at the center collaborate with surgical and imaging experts at the Massachusetts Eye and Ear Infirmary (MEEI) and use advanced imaging technologies, including CT, MRI, and PET/CT, to provide comprehensive care. Therefore, awareness programs on cancer-causing viruses such as human papillomavirus (HPV) and the presence of dedicated head and neck cancer treatment programs are urging the adoption of cancer treatment procedures and driving the growth of the head and neck cancer treatment market in the region.

The outbreak of COVID-19 affected all countries in North America, especially the US. It also had a slight adverse effect on the head and neck cancer treatment market in the region. Hence, the adoption of head and neck cancer treatments lowered slightly, which affected the growth of the regional market in 2020 and Q1 2021 to some extent. Nevertheless, in 2021, limitations were relieved with the initiation of large-scale COVID-19 vaccination drives in various countries in the region to prevent the spread of the disease, which allowed the resumption of business activities. The ease of the restrictions encouraged people to go for health checkups and treatments, which expanded the demand for cancer diagnostics and treatment, which had been delayed due to COVID-19 and, in turn, fuelled the growth of the head and neck cancer treatment market in North America in 2022. The regional market is expected to grow during the forecast period.

Buy Now Full Report and Discover More

Key Head and Neck Cancer Treatment Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 10 market companies, including:

Amgen Inc. - The company offers head and neck cancer treatment solutions such as Vectibix as a first-line treatment in patients with recurrent and metastatic squamous cell head and neck cancer.

• Amgen Inc.
• AstraZeneca Plc
• Ayala Pharmaceuticals Inc.
• Bristol Myers Squibb Co.
• Debiopharm International SA
• Eli Lilly and Co.
• Incyte Corp.
• Merck and Co. Inc.
• Novartis AG, Pfizer Inc.
• Sanofi

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Head and Neck Cancer Treatment Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Head and Neck Cancer Treatment Market Drivers

The increasing incidence of head and neck cancers is notably driving the market growth.  Head and neck cancers include cancers in the oral cavity, pharynx (nasopharynx, oropharynx, and hypopharynx), larynx, paranasal sinuses and nasal cavity, and salivary glands. Generally, head and neck cancers are attributed to squamous cell carcinoma (SCC), which is mostly diagnosed late with a poor prognosis and is particularly prevalent among men who have a significant history of alcohol consumption and/or tobacco use. SCCHN develops around the mucosal linings of the upper aerodigestive tract.

SCCHN is the sixth-leading cancer in terms of incidence, with about half a million new cases diagnosed every year globally. Head and neck cancers accounted for about 4% of all cancers in the US, and also estimated 562,328 people worldwide were diagnosed with head and neck cancer in 2020. In the US, according to the Centers for Disease Control and Prevention (CDC), the human papillomavirus (HPV) is responsible for about 70% of all oropharyngeal cancer. The number of new cases of HPV-associated oropharyngeal cancers diagnosed every year in men is about 15,500, while that in women is about 3,500. According to the National Health Service (NHS) in the UK, about 12,000 new cases of head and neck cancer are diagnosed annually in the UK. Furthermore, about 8,300 people are diagnosed with mouth cancer in the UK every year, which contributes to 1 out of every 50 cancers that are diagnosed. Therefore, such factors are expected to drive the growth of the global head and neck cancer treatment market during the forecast period.

Significant Head and Neck Cancer Treatment Market Trends

The growing trend of oncology-related medical tourism is an emerging trend shaping market growth. Current advancements in medical technology allow the reduction or complete cure of cancer. The latest medical treatment is not always available or accessible to everyone owing to several reasons, including its affordability. Oncology treatment can be very costly. In the US, some diagnostic procedures and treatment cycles can be very costly, but the same procedure may be less expensive in other countries, such as India. People prefer to travel to foreign destinations that deliver cost-effective and high-quality healthcare treatment and care. The typical types of cancer treatments for which patients travel abroad include radiation therapy, medical/surgical oncology, chemotherapy, targeted/proton therapy, head and neck cancer therapeutics and immunotherapy. The most prevalent medical tourism destinations for cancer treatment are Germany, Spain, France, India, and Israel. Germany offers superior technology-based treatments, while France has the highest success rate in Europe, and Spain focuses on providing alternative treatment options for oncology. On the other hand, developing countries such as India provides up-to-date oncology diagnostics and treatment methods at cost-effective rates, while Israel is a favoured option for its highly advanced facilities. Consequently, the growing trend of oncology-related medical tourism is likely to positively impact the demand for diagnostics and treatment in the head and neck cancer treatment market during the forecast period.

Major Head and Neck Cancer Treatment Market Challenges

Lack of access to quality healthcare in underdeveloped regions is a significant challenge hindering market growth. Low- and middle-income countries bear most of the disease burden but contribute a meager share to overall global healthcare expenditure. The rapid population growth rate in many developing countries necessitates advancement in the quality of both healthcare and related infrastructure. Nevertheless, various factors are responsible for the restricted access to healthcare in the least developing countries, including the lack of knowledge, resources, shortage of trained medical practitioners, and the high cost of head and neck cancer drugs. In many underdeveloped and developing regions, the lack of knowledge and awareness is compounded by the lack of proper healthcare infrastructure. Further, the dearth of trained medical practitioners is widespread in underdeveloped regions. Consequently, the overall healthcare system in most of these countries requires numerous reforms to meet the rising demand for quality healthcare. Despite foreign investments from global institutions, such as The World Bank Group, WHO, and the Bill and Melinda Gates Foundation, along with several other non-profit organizations and local governments, the disparities in healthcare systems continue to exist in poorer, underdeveloped, and developing countries. Thus, the lack of awareness and restricted access to healthcare hinder the growth of the global head and neck cancer treatment market during the forecast period.

Buy Now Full Report and Discover More

Key Head and Neck Cancer Treatment Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Head and Neck Cancer Treatment Market Customer Landscape

Segment Overview

The head and neck cancer treatment market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Route Of Administration Outlook (USD Million, 2017 - 2027)
  • Injectable
  • Oral

• Therapy Outlook (USD Million, 2017 - 2027)
  • Immunotherapy
  • Targeted therapy
  • Chemotherapy

• Region Outlook (USD Million, 2017 - 2027)
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Australia
    • Argentina
    • Rest of the world

Head and Neck Cancer Treatment Market Scope
Report Coverage	Details
Page number	159
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 11.27%
Market growth 2023-2027	USD 5,077.38 million
Market structure	Concentrated
YoY growth 2022-2023(%)	10.57
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 41%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Amgen Inc., AstraZeneca Plc, Ayala Pharmaceuticals Inc., Bristol Myers Squibb Co., Debiopharm International SA, Eli Lilly and Co., Incyte Corp., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Head and Neck Cancer Treatment Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the head and neck cancer treatment market between 2023 and 2027
• Precise estimation of the head and neck cancer treatment market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on the company's position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of the head and neck cancer treatment market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch